Weight | 1 lbs |
---|---|
Dimensions | 9 × 5 × 2 in |
host | rabbit |
isotype | IgG |
clonality | polyclonal |
concentration | 1 mg/mL |
applications | ICC/IF, WB |
reactivity | Bim (IN) |
available sizes | 100 µg |
rabbit anti-Bim (IN) polyclonal antibody 1410
$445.00
Antibody summary
- Rabbit polyclonal to Bim (IN)
- Suitable for: ELISA,WB,IHC-P,IF
- Isotype: IgG
- 100 µg
rabbit anti-Bim (IN) polyclonal antibody 1410
antibody |
---|
Tested applications WB,IHC,IHC,ICC/IF,ELISA |
Recommended dilutions Immunoblotting: use at 1ug/mL. Immunocytochemistry: use a 10-20ug/mL These are recommended concentrations. Enduser should determine optimal concentration for their application. Positive control: Whole cell lysate of human K562 cells. |
Immunogen Peptide corresponding to aa 22-40 of human Bim. The sequence is identical to that of mouse and is different by one amino acid from that of rat. |
Size and concentration 100µg and lot specific |
Form liquid |
Storage Instructions This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles. |
Storage buffer PBS, pH 7.4. |
Purity peptide affinty purifcation |
Clonality polyclonal |
Isotype IgG |
Compatible secondaries goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863 goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720 |
Isotype control Rabbit polyclonal - Isotype Control |
target relevance |
---|
Protein names Bcl-2-like protein 11 (Bcl2-L-11) (Bcl2-interacting mediator of cell death) |
Gene names BCL2L11,BCL2L11 BIM |
Protein family Bcl-2 family |
Mass 22171Da |
Function Induces apoptosis and anoikis. Isoform BimL is more potent than isoform BimEL. Isoform Bim-alpha1, isoform Bim-alpha2 and isoform Bim-alpha3 induce apoptosis, although less potent than isoform BimEL, isoform BimL and isoform BimS. Isoform Bim-gamma induces apoptosis. Isoform Bim-alpha3 induces apoptosis possibly through a caspase-mediated pathway. Isoform BimAC and isoform BimABC lack the ability to induce apoptosis. |
Subellular location Endomembrane system ; Peripheral membrane protein. Note=Associated with intracytoplasmic membranes.; [Isoform BimEL]: Mitochondrion. Note=Translocates from microtubules to mitochondria on loss of cell adherence.; [Isoform BimL]: Mitochondrion.; [Isoform BimS]: Mitochondrion.; [Isoform Bim-alpha1]: Mitochondrion. |
Tissues Isoform BimEL, isoform BimL and isoform BimS are the predominant isoforms and are widely expressed with tissue-specific variation. Isoform Bim-gamma is most abundantly expressed in small intestine and colon, and in lower levels in spleen, prostate, testis, heart, liver and kidney. |
Structure Forms heterodimers with a number of antiapoptotic Bcl-2 proteins, including MCL1, BCL2, BCL2L1 isoform Bcl-X(L), BCL2A1/BFL-1, BHRF1, and BCL2L2/BCLW (PubMed:11997495, PubMed:27013495, PubMed:18812174). Does not heterodimerize with proapoptotic proteins such as BAD, BOK or BAK. Identified in a complex containing BCL2L11, DYNLL1 and BCL2L1 isoform Bcl-X(L); BH3 integrity is required for BCL2L1-binding. Interacts with YWHAZ. When phosphorylated, interacts with TRIM2; this interaction is associated with ubiquitination and degradation (PubMed:21478148). Interacts with MCL1; may sequester BCL2L11 to prevent its pro-apoptotic activity (PubMed:27013495, PubMed:17389404). Interacts with GIMAP5 (PubMed:16509771). Interacts with BCL2L10/BCL-B (PubMed:23235460, PubMed:23563182, PubMed:22498477).; [Isoform BimEL]: Interacts (when phosphorylated) with USP27X; the interaction leads to BCL2L11 deubiquitination and stabilization (PubMed:27013495). Interacts with humanin; the interaction prevents BIM-induced apoptosis.; [Isoform BimL]: Does not interact with humanin.; [Isoform BimS]: Interacts with BAX; the interaction may lead to BAX activation through conformational change (PubMed:11997495). Does not interact with humanin (PubMed:15661735).; [Isoform Bim-alpha3]: Interacts with BAX; the interaction may lead to BAX activation through conformational change. |
Post-translational modification Phosphorylation at Ser-69 by MAPK1/MAPK3 leads to interaction with TRIM2 and polyubiquitination, followed by proteasomal degradation (PubMed:15486195, PubMed:21478148). Deubiquitination catalyzed by USP27X stabilizes the protein (By similarity).; Ubiquitination by TRIM2 following phosphorylation by MAPK1/MAPK3 leads to proteasomal degradation. Conversely, deubiquitination catalyzed by USP27X stabilizes the protein. |
Target Relevance information above includes information from UniProt accession: O43521 |
The UniProt Consortium |
Data
Publications
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.pmid | title | authors | citation |
---|
Protocols
relevant to this product |
---|
Western blot IHC ICC |
Documents
# | |||
---|---|---|---|
Please enter your product and batch number here to retrieve - product datasheet, SDS, and QC information. |
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.